Risk of Development of In Vitro Resistance to Amoxicillin, Clarithromycin, and Metronidazole in Helicobacter pylori

Size: px
Start display at page:

Download "Risk of Development of In Vitro Resistance to Amoxicillin, Clarithromycin, and Metronidazole in Helicobacter pylori"

Transcription

1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1998, p Vol. 42, No /98/$ Copyright 1998, American Society for Microbiology Risk of Development of In Vitro Resistance to Amoxicillin, Clarithromycin, and Metronidazole in Helicobacter pylori MIKAEL SÖRBERG, 1 * HÅKAN HANBERGER, 2 MAUD NILSSON, 3 ANDERS BJÖRKMAN, 1 AND LENNART E. NILSSON 3 Department of Infectious Diseases, Danderyd Hospital, S Danderyd, 1 and Infectious Diseases 2 and Department of Clinical Microbiology, 3 University Hospital, S Linköping, Sweden Received 11 August 1997/Returned for modification 3 December 1997/Accepted 12 February 1998 We have studied initial killing, morphological alterations, the frequency of occurrence, and the selective growth of resistant subpopulations of Helicobacter pylori during exposure to amoxicillin, clarithromycin, or metronidazole by bioluminescence assay of intracellular ATP levels, microscopy, and a viable count assay. We found an induction of spheroplasts and a decrease in intracellular ATP levels after 21 h of exposure to high concentrations of amoxicillin. During clarithromycin exposure the onset of a decrease in intracellular ATP levels started after prolonged incubation, and with the highest concentration of clarithromycin an induction of coccoid forms was seen after 68 h. Metronidazole exposure resulted in the strongest initial decrease in intracellular ATP levels, and coccoid forms were seen after 21 h of exposure to high concentrations of metronidazole. Amoxicillin caused a low-level increase in resistant subpopulations, which indicates a need for surveillance of the amoxicillin susceptibility of H. pylori in order to detect decreasing susceptibility. No increase in the numbers of resistant subpopulations was demonstrated during clarithromycin exposure. Metronidazole selected resistant subpopulations, which caused high-level resistance in H. pylori. Helicobacter pylori infection is a principal cause of chronic gastritis type B (13) and is associated with gastric cancer (19, 20, 33). Eradication of H. pylori prevents relapse of duodenal ulcer, and treatment of this infection has now become standard for patients with peptic ulcer disease (22, 37). The regimen most widely used today to eradicate H. pylori is combination therapy with two antibiotics and bismuth (17, 27) or an acid pump inhibitor (3, 22). A major reason for H. pylori eradication failure is resistance to metronidazole (4, 5, 9, 17, 27, 29, 34, 36) or clarithromycin (11, 44). In contrast, H. pylori does not appear to develop resistance to amoxicillin (16). The prevalence of primary metronidazole resistance varies between 7 and 90% (2, 9, 14, 36), with the highest prevalences occurring in people from developing countries (2, 9, 14), after previous metronidazole ingestion (2, 14), and in women (2, 14, 36). The prevalence of primary clarithromycin resistance is between 4 and 7% (12, 16, 45). The development of resistance during therapy has been observed for both metronidazole (35, 36, 46) and clarithromycin (11, 26, 43). The aim of this study was to evaluate the initial killing, morphological alterations, and the frequency of occurrence and the selective growth of resistant subpopulations of H. pylori during exposure to amoxicillin, clarithromycin, or metronidazole. * Corresponding author. Mailing address: Department of Infectious Diseases, Danderyd Hospital, S Danderyd, Sweden. Phone: Fax: Mikael.Sorberg@kids.ki.se. MATERIALS AND METHODS Bacterial strain. H. pylori NCTC was used in the present study. Antibiotics. Amoxicillin and metronidazole were purchased from Sigma Chemical Co., St. Louis, Mo. Clarithromycin was kindly provided by Abbott Laboratories, Chicago, Ill. Growth medium. Mueller-Hinton broth (MHB; Gibco Limited, Renfrewshire, Scotland) supplemented with 50 mg of Ca 2 per liter, 25 mg of Mg 2 per liter, and 1% fetal calf serum was used as the growth medium. Bioluminescence assay of intracellular ATP levels. A 100- l sample from the bacterial culture was incubated at 37 C for 10 min with 100 l of the ATPhydrolyzing enzyme apyrase, purified grade I (Sigma Chemical Co.) in supplemented MHB, to eliminate extracellular ATP. A 50- l sample of the apyrasetreated sample was pipetted into 500 l of boiling 0.1 M Tris buffer (ph 7.75) containing 2 mm EDTA to release the intracellular ATP and inactivate the apyrase. After being heated for 90 s, the extracts were cooled before the intracellular ATP levels were assayed. This extraction was performed in an LKB Biocal 2030 incubator (LKB Products, Bromma, Sweden). Luciferase reagent (100 l) was added to 550 l of each cooled extract, and the light intensity was measured in a 1250 Luminometer (LKB Wallac, Turku, Finland) and was recorded on a 1250 Display (LKB Wallac). An ATP-monitoring reagent (Bio Orbit, Turku, Finland) was used in the assay of ATP levels. The ATP levels in the samples were calculated by using the results of assays of standard amounts of ATP as a reference. A correction was made for background luminescence. Extracts to which known amounts of ATP were added were used as internal standards in order to correct for inhibition of the luciferase reaction by the reagents. The coefficient of variation for the bioluminescence assay has been shown to vary between 1.7 and 6.5% (41). Monitoring of bacterial growth during antibiotic exposure in broth. The bacterial numbers were determined by the bioluminescence assay of bacterial ATP levels. As indicated by Thore et al. (42) and Molin et al. (30), 10 6 M ATP corresponded to approximately 10 9 bacteria/ml. From a culture with bacteria in the log phase diluted to 10 7 CFU/ml, 5 ml was transferred to 50-ml Erlenmeyer flasks containing 50 l of antibiotics at different concentrations. The concentrations tested were as follows: amoxicillin, to 0.25 g/ml; clarithromycin, to 0.25 g/ml; and metronidazole, 0.06 to 32 g/ml. Samples were taken daily for bioluminescence assay of intracellular bacterial ATP levels. The flasks were incubated at 37 C under microaerobic conditions (5% oxygen, 10% carbon dioxide, 85% nitrogen) in an incubator box (ASSAB with CO 2 and O 2 regulator; Kebo Biomed, Spånga, Sweden). The experiments were repeated three times. Morphology. The bacteria were exposed to amoxicillin, clarithromycin, and metronidazole and were studied by light microscopy at a magnification of 1,250 after being stained with acridine orange (28). The sensitivity of the staining method is 10 4 CFU/ml (28). Population analysis. Population analyses were performed with control cultures and regrowing cultures exposed to metronidazole or amoxicillin. Population analyses were also performed with cultures that grew in the presence of the highest concentration during clarithromycin exposure. The contents of the flasks were thoroughly mixed, and 0.1-ml portions were removed and diluted serially in 0.9-ml aliquots of phosphate-buffered saline. A total of 50 l from each dilution was dropped onto paper disc method (PDM) agar plus 5% defibrinated horse blood (AB Biodisk, Solna, Sweden) containing different concentrations of amoxicillin ( to 0.25 g/ml), clarithromycin ( to 0.25 g/ml), and metronidazole (0.06 to 32 g/ml). The drops were allowed to dry at room temperature. The plates were incubated for 5 days at 37 C under microaerobic conditions, and the colonies were then counted. The frequencies of occurrence of variants resistant to different concentrations of amoxicillin, clarithromycin, and metronidazole were calculated by dividing the number of colonies on plates with antibiotic 1222

2 VOL. 42, 1998 IN VITRO DRUG RESISTANCE IN H. PYLORI 1223 FIG. 1. Monitoring of growth of H. pylori assayed by bioluminescence assay of ATP levels in bacteria in an unexposed culture ( ) and cultures exposed to amoxicillin at (F), ( ), 0.03 (E), and 0.25 ({) g/ml. by the number of colonies on plates without antibiotic. The experiments were repeated three times. Ten passages of the metronidazole-resistant cultures were done in drug-free MHB. Susceptibility testing on agar plates was done with passaged cultures in antibiotic-free broth by the E-test (AB Biodisk). Determination of antibiotic concentrations in H. pylori cultures. Samples from H. pylori cultures exposed to 0.25 g of amoxicillin per ml, 0.25 g of clarithromycin per ml, or 32 g of metronidazole per ml were taken after 0, 21, 46, 68, 96, 118, 142, 166, 191, 214, and 267 h incubation at 37 C under microaerobic conditions. The samples were put in wells of a PDM agar (AB Biodisk) tray with Micrococcus luteus ATCC 9341 for determination of amoxicillin and clarithromycin concentrations and in wells of a PDM agar plus 5% defibrinated horse blood (AB Biodisk, Solna, Sweden) tray with Clostridium perfingens ATCC for determination of metronidazole concentration. The trays with M. luteus were incubated overnight under aerobic conditions, and the trays with C. perfringens were incubated overnight under anaerobic conditions. The resulting inhibition zones surrounding the wells were measured and were compared with those obtained by linear regression analysis with standard concentrations of drugs. RESULTS Growth and morphology of H. pylori during exposure to amoxicillin. Growth of the cultures with an inoculum of M ATP was monitored, and three growth patterns were seen. Intracellular ATP levels increased in the cultures exposed to low concentrations of amoxicillin ( g/ml) (Fig. 1). There was an initial growth inhibition in the cultures exposed to g of amoxicillin per ml (Fig. 1). The cultures exposed to g of amoxicillin per ml showed an initial decrease in intracellular ATP levels after 46 h (Fig. 1). Microscopy showed spheroplasts in cultures in which a decrease in intracellular ATP levels occurred. After 118 h a few bacillary forms were seen, and the numbers of these forms increased when the intracellular ATP level in these cultures increased. There was no decrease in the amoxicillin concentration in the broth cultures containing and g of amoxicillin per ml when regrowth occurred. In the culture exposed to 0.03 g of amoxicillin per ml, intracellular ATP levels increased after 191 h, and microscopy showed a mixed population of bacillary forms, spheroplasts, and coccoid cells. In this culture there was a reduction in the amoxicillin concentration, and at 191 h, when the culture regrew, only 50% of the initial amoxicillin concentration was left in the broth. At concentrations above 0.03 g of amoxicillin per ml there was no regrowth. Population analyses of cultures exposed to amoxicillin. Population analyses were performed with the unexposed cultures and cultures exposed to amoxicillin at concentrations of 0.008, 0.015, and 0.03 g/ml. The bacteria in the unexposed cultures were resistant to up to g/ml (Fig. 2). At higher concentrations on agar plates there was a reduction in the frequency of resistant variants for the unexposed broth cultures (Fig. 2). The cultures exposed to and g of amoxicillin per ml in broth were resistant to up to g/ml, and the frequency of resistant variants exposed to amoxicillin at 0.03 g/ml was 10 1 (Fig. 2). The frequency of resistant variants in the cultures exposed to 0.03 g of amoxicillin per ml was lower than that for the unexposed cultures (Fig. 2). Population analyses were performed with the control cultures on two different occasions with an interval of 3 days, and no reduction in the amoxicillin concentrations on the agar plates was found. Growth and morphology of H. pylori during exposure to clarithromycin. Growth of the cultures with an inoculum of M ATP was monitored. Intracellular ATP levels increased in the cultures exposed to low concentrations of clarithromycin ( 0.06 g/ml) (Fig. 3). There was a concentration-dependent inhibition of the increase in intracellular ATP levels, and after prolonged incubation there was a concentration-dependent decrease in intracellular ATP levels in the cultures (Fig. 3). Microscopy showed bacillary forms in the growing cultures, and a conversion from bacillary to coccoid forms was seen when the intracellular ATP levels decreased. No cultures showed regrowth. The clarithromycin concentrations in broth were stable throughout the experiment. Population analyses of cultures exposed to clarithromycin. Population analyses were performed with the unexposed cultures and cultures exposed to clarithromycin at concentrations of and g/ml. The unexposed cultures and the cultures exposed to g of clarithromycin per ml were resistant to up to g/ml (Fig. 4). At higher concentrations there was a reduction in the frequency of resistant variants to 10 1 after exposure to clarithromycin at 0.03 g/ml (Fig. 4). For cultures exposed to g of clarithromycin per ml the frequency of resistant variants was lower after exposure

3 1224 SÖRBERG ET AL. ANTIMICROB. AGENTS CHEMOTHER. FIG. 2. Population analysis of H. pylori in unexposed cultures ( and ) and cultures exposed to amoxicillin at (F), ( ) and 0.03 (E) g/ml. to clarithromycin at and 0.03 g/ml than that for the unexposed cultures and the cultures exposed to g of clarithromycin per ml (Fig. 4). Population analyses were performed with the control cultures on two different occasions with an interval of 3 days, and no reduction in the clarithromycin concentration in the agar plates was found. Growth and morphology of H. pylori during exposure to metronidazole. Growth of the cultures with an inoculum of M ATP was monitored, and two growth patterns were seen. Intracellular ATP levels increased in the cultures exposed to low concentrations of metronidazole ( 0.5 g/ml) (Fig. 5). The cultures exposed to 1 to 32 g of metronidazole per ml showed an initial decrease in intracellular ATP levels (Fig. 5), and microscopy showed a conversion from bacillary to coccoid forms after 21 h. When the intracellular ATP levels increased in the cultures exposed to 1 to 4 g of metronidazole per ml, a change in morphology was seen by microscopy, from coccoid forms to bacillary forms. In cultures with concentrations above 4 g of metronidazole per ml there was no regrowth (Fig. 5). The metronidazole concentrations in broth were stable throughout the experiment. Population analyses of cultures exposed to metronidazole. Population analyses were performed with the unexposed cultures and cultures exposed to metronidazole at concentrations of1to4 g/ml. The bacteria in the unexposed cultures were resistant to up to 0.25 g/ml (Fig. 6). With higher concentrations there was a reduction in the frequency of resistant variants for the unexposed cultures (Fig. 6). For the cultures ex- FIG. 3. Monitoring of growth of H. pylori assayed by bioluminescence assay of ATP levels in bacteria in an unexposed culture ( ) and cultures exposed to clarithromycin at to 0.25 g/ml ({, g/ml; }, g/ml; Œ, g/ml; E, g/ml;, g/ml; F, g/ml).

4 VOL. 42, 1998 IN VITRO DRUG RESISTANCE IN H. PYLORI 1225 FIG. 4. Population analysis of H. pylori in unexposed cultures ( and ) and cultures exposed to clarithromycin at (F) and ( ) g/ml. 5E-04, posed to 1 to 4 g of metronidazole per ml, resistant variants were resistant to up to 32 g/ml (Fig. 6). The selection of resistant variants was concentration dependent, and after exposure to the highest concentration (4 g of metronidazole per ml) all bacteria in the population were resistant to metronidazole at 32 g/ml (Fig. 6). Population analyses were performed with the control cultures on three different occasions with a total interval of 13 days, and no reduction in the metronidazole concentrations on the agar plates was found (Fig. 6). The resistance remained stable through 10 passages in MHB for all cultures in which metronidazole resistance developed. DISCUSSION This study showed an initial decrease in intracellular ATP levels during exposure of H. pylori to high concentrations of amoxicillin (Fig. 1), and this bactericidal effect of amoxicillin is in agreement with the effect found in a study by Berry et al. (6). During exposure of H. pylori to amoxicillin, microscopy showed spheroplasts after 21 h, which is in accordance with the findings of a study by Nilius et al. (32) and a previous study by us (40), in which we found a concentration-dependent induction of spheroplasts after only 2 h. Other investigators have reported a morphologic conversion of H. pylori during exposure to FIG. 5. Monitoring of growth of H. pylori assayed by bioluminescence assay of ATP levels in bacteria in an unexposed culture ( ) and cultures exposed to metronidazole at 0.5 to 4 and 32 g/ml (}, 32 g/ml; F, 4 g/ml;, 2 g/ml; E, 1 g/ml; {, 0.5 g/ml).

5 1226 SÖRBERG ET AL. ANTIMICROB. AGENTS CHEMOTHER. FIG. 6. Population analysis of H. pylori in an unexposed cultures (,, and Œ) and cultures exposed to metronidazole at 1 to 4 g/ml (E, 1 g/ml;, 2 g/ml; F, 4 g/ml). amoxicillin but have not distinguished between coccoid forms and spheroplasts (6, 7). Armstrong et al. (1) reported central clearing and vesiculation of H. pylori after a 24-h exposure to amoxicillin but did not discuss these findings in terms of coccoid forms or spheroplasts. No reports on the clinical significance of amoxicillin resistance in H. pylori have been published, and Glupczynski et al. (16) found an unchanged susceptibility of H. pylori to amoxicillin over a 5-year period. We found a small increase in the numbers of resistant subpopulations in all except one of the regrowing cultures exposed to amoxicillin. In one culture (containing 0.03 g of amoxicillin per ml), regrowth occurred after 191 h due to a decrease in the concentration of amoxicillin in the broth (Fig. 2). Our results are in agreement with those of Haas et al. (18), who found increased amoxicillin MICs during exposure to amoxicillin in several passages. Our results and those of Haas et al. (18) indicate that there is a need for surveillance of the amoxicillin susceptibility of H. pylori in order to detect decreasing levels of susceptibility. After a prolonged incubation, clarithromycin exposure resulted in a concentration-dependent decrease in intracellular ATP levels in H. pylori cultures (Fig. 3). Similar results were found by Flamm et al. (15), who demonstrated a bactericidal effect of clarithromycin on H. pylori after 8 h of exposure to clarithromycin. In an earlier study (40) we could not find any bactericidal effect after 5 h of exposure of H. pylori to clarithromycin, but this was probably due to a shorter exposure time. A conversion from bacillary to coccoid forms was seen in this study after 68 h of exposure of H. pylori to the highest concentration of clarithromycin. After the same exposure time, Nilius et al. (32) found an induction of coccoid forms during exposure of H. pylori to erythromycin. We found no regrowth or increase in the numbers of resistant subpopulations of H. pylori during clarithromycin exposure (Fig. 4). Haas et al. (18) found variation among different strains, with increasing MICs for H. pylori during exposure to erythromycin. This variation among different strains might explain why we did not find resistant subpopulations of the strain used in our study. The strongest initial decrease in intracellular ATP levels was seen during exposure of H. pylori to metronidazole (Fig. 5), and this bactericidal effect of metronidazole on H. pylori has also been demonstrated by Armstrong et al. (1). We found a conversion from bacillary to coccoid forms after 21 h in the cultures in which a decrease in intracellular ATP levels occurred. This is similar to the results of a study by Armstrong et al. (1), who reported a conversion to coccoid forms after 48 h of exposure of H. pylori to metronidazole. The mechanisms for metronidazole resistance are probably a decreased ability of metronidazole-resistant strains to achieve a sufficiently low redox potential under microaerobic conditions for the necessary reduction of metronidazole and that during short periods of anaerobic conditions these strains manage to reduce and store sufficient amounts of metronidazole so as to appear fully susceptible after subsequent incubation under microaerobic conditions (8, 38, 48). This leads to a slower uptake of metronidazole by resistant strains of H. pylori than by sensitive strains, which has been reported by several investigators (25, 31, 38). We found selection and regrowth of resistant subpopulations of H. pylori in all regrowing cultures during exposure to metronidazole (Fig. 6). During this regrowth a change in morphology from coccoid to bacillary forms was seen by microscopy. This change is probably due to a low frequency of occurrence of resistant subpopulations rather than a conversion from coccoid to bacillary forms. This caused a decreased susceptibility to metronidazole, which is in agreement with the findings of Haas et al. (18), who reported an increase in the MIC of metronidazole for H. pylori after several passages during exposure to metronidazole. When evaluating the development of resistance to metronidazole during treatment, it is important to study whether there is a selection of spontaneous resistant variants of the infecting strain or whether there is reinfection with an exogenous strain (23, 35). The metronidazole resistance in our study was stable during 10 passages, which is in agreement with the findings of a study by Haas et al. (18), but there have also been reports of unstable metronidazole resistance. Zwet et al. (48) found that metronidazole resistance induced in vitro was reversed in 30% of the isolates by further culture on antibiotic-free plates. The different results concerning the stability of metronidazole resistance might be explained by methodological differences such as the use of

6 VOL. 42, 1998 IN VITRO DRUG RESISTANCE IN H. PYLORI 1227 different inocula (21) and by the use of different incubation conditions (8, 38, 47). When studying the morphology of H. pylori it is important to differentiate between coccoid cells (1, 6) and spheroplasts (32). In our earlier study we found a rapid induction of spheroplasts during exposure of H. pylori to amoxicillin (40), while the rate of conversion to coccoid forms during exposure to clarithromycin and metronidazole in this study was slower. The spheroplasts are larger than the coccoid forms seen by microscopy (unpublished results). The coccoid forms changed color, from orange to green, during prolonged exposure to clarithromycin and metronidazole when acridine orange staining was used (unpublished results). A cell containing more RNA than DNA stains orange, and a cell in which much of the RNA has been degraded but still retains its DNA stains green (24). The degradation of RNA has been correlated with a loss of viability (10). The spheroplasts stained orange (unpublished results), and we found in an earlier study (40) that they reverted to bacillary forms. In another previous study (39) we found a low ATP level in the coccoid cell during prolonged incubation of H. pylori, but we were not able to demonstrate a conversion to bacillary forms. In conclusion, we found an induction of spheroplasts and a decrease in intracellular ATP levels after 21 h of exposure of H. pylori to high concentrations of amoxicillin. During clarithromycin exposure the onset of the decrease in intracellular ATP levels started after prolonged incubation, and with the highest concentration of clarithromycin an induction of coccoid forms was seen after 68 h. Metronidazole exposure resulted in the strongest initial decrease in intracellular ATP levels, and coccoid forms were seen after 21 h of exposure to high concentrations of metronidazole. Amoxicillin caused a low-level increase in the numbers of resistant subpopulations, which indicates that there is a need for surveillance of the amoxicillin susceptibility of H. pylori in order to detect decreasing susceptibility. No increase in resistant subpopulations was demonstrated during clarithromycin exposure. Metronidazole selected resistant subpopulations, which caused high-level resistance in H. pylori. REFERENCES 1. Armstrong, J. A., S. H. Wee, C. S. Goodwin, and D. H. Wilson Response of Campylobacter pyloris to antibiotics, bismuth and an acidreducing agent an ultrastructural study. J. Med. Microbiol. 24: Banatvala, N., G. R. Davies, Y. Abdi, A. Clements, D. S. Rampton, J. M. Hardie, and R. A. Feldman High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease. Gut 35: Bazzoli, F., R. M. Zagari, S. Fossi, P. Pozzato, G. Alampi, P. Simoni, S. Sottili, A. Roda, and E. Roda Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur. J. Gastroenterol. Hepatol. 6: Bell, G. D., K. Powell, S. M. Burridge, A. F. Bowden, W. Atoyebi, G. H. Bolton, P. H. Jones, and C. Browns Rapid eradication of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 9: Bell, G. D., K. Powell, S. M. Burridge, A. Pallecaros, P. H. Jones, P. W. Gant, G. Harrison, and J. E. Trowell Experience with triple anti-helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment. Pharmacol. Ther. 6: Berry, V., K. Jennings, and G. Woodnutt Bacteriocidal and morphological effect of amoxicillin on Helicobacter pylori. Antimicrob. Agents Chemother. 39: Bode, G., F. Mauch, P. Malfertheiner The coccoid form of Helicobacter pylori. Criteria for their viability. Epidemiol. Infect. 111: Cederbrant, G., G. Kahlmeter, and Å. Ljungh Proposed mechanism for metronidazole resistance in Helicobacter pylori. J. Antimicrob. Chemother. 29: Ching, C. K., K. P. Leung, R. W. Yung, S. K. Lam, B. C. Wong, K. C. Lai, and C. L. Lai Prevalence of metronidazole resistance Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. Gut 38: Davis, B. D., S. J. Lager, and P. C. Tai Role of ribosome degradation in the death of starved Escherichia coli cells. J. Bacteriol. 166: Debets-Ossenkopp, Y. J., M. Sparrius, J. G. Kusters, J. J. Kolkman, and C. M. Vandenbroucccke-Grauls Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori. FEMS Microbiol. Lett. 142: De Koster, E., A. Cozzoli, C. Jonas, R. Ntounda, J. P. Butzler, and M. Detenre Six years resistance of Helicobacter pylori to macrolides and imidazoles. Gut 39(Suppl. 2):A5. (Abstract 1A:04.) 13. Dixon, M. F., and G. M. Sobala Gastritis and duodenitis: histopathological spectrum. Eur. J. Gastroenterol. Hepatol. 4(Suppl. 2): European Study Group on Antibiotic Susceptibility of Helicobacter pylori Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. Eur. J. Microbiol. Infect. Dis. 11: Flamm, R. K., J. Beyer, S. K. Tanaka, and J. Clement Kill kinetics of antimicrobial agents against Helicobacter pylori. J. Antimicrob. Chemother. 38: Glupczynski, Y., S. Goutier, C. van den Borre, J. P. Butzler, and A. Burette Surveillance of Helicobacter pylori resistance to antimicrobial agents in Belgium from 1989 to Gut 37(Suppl. 1):A56. (Abstract 223.) 17. Graham, D. Y., G. M. Lew, H. M. Malaty, D. Evans, P. Klein, and L. Alpert Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 102: Haas, C. E., D. E. Nix, and J. J. Schentag In vitro selection of resistant Helicobacter pylori. Antimicrob. Agents Chemother. 34: Hansson, L. E., L. Engstrand, O. Nyren, D. J. Evans, A. Lindgren, and R. Bergström Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma. Gastroenterology 105: Hansson, L. E., L. Engstrand, O. Nyren, and A. Lindgren Prevalence of Helicobacter pylori infection in subtypes of gastric cancer. Gastroenterology 109: Henriksen, T. H., Ö. Brorson, R. Schöyen, and T. Thoresen Risks related to lack of standardization of tests to detect in vitro metronidazole resistance in Helicobacter pylori. Eur. J. Microbiol. Infect. Dis. 15: Hentchel, E., G. Brandsätter, B. Dragosics, A. M. Hirschl, H. Nemec, and K. Schutze Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and recurrence of duodenal ulcer. N. Engl. J. Med. 328: Jorgensen, M., G. Daskalopoulos, V. Warburton, H. M. Mitchell, and S. L. Hazell Multiple strain colonization and metronidazole resistance in Helicobacter pylori-infected patients: identification from sequential and multiple biopsy specimens. J. Infect. Dis. 174: Kasten, F. H Cytochemical studies with acridine orange and the influence of dye contaminants in staining of nucleic acid. Int. Rev. Cytol. 21: Lacey, S. L., S. F. Moss, and G. W. Taylor Metronidazole uptake by sensitive and resistant isolates of Helicobacter pylori. J. Antimicrob. Chemother. 32: Logan, R. P., P. A. Gummet, H. D. Schaufelberger, R. R. Greaves, G. M. Mendelson, and M. M. Walker Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 35: Logan, R. P., P. A. Gummet, J. J. Misiewicz, Q. N. Karim, M. M. Walker, and J. H. Baron One week eradication regimen for Helicobacter pylori. Lancet 338: McCarthy, L. R., and J. E. Senne Evaluation of acridine orange stain for detection of microorganisms in blood cultures. J. Clin. Microbiol. 11: Midola, P. H., J. R. Lambert, and J. Turnidge Metronidazole resistance: a predictor of failure of Helicobacter pylori eradication by triple therapy. J. Gastroenterol. Hepatol. 11: Molin, Ö., L. Nilsson, and S. Ånsehn Rapid detection of bacterial growth in blood cultures by bioluminescent assay of bacterial ATP. J. Clin. Microbiol. 18: Moore, R. A., B. Beckthold, and L. E. Bryan Metronidazole uptake in Helicobacter pylori. Can. J. Microbiol. 41: Nilius, M., A. Ströhle, G. Bode, and P. Malfertheiner Coccoid like form(clf) of Helicobacter pylori. Enzyme activity and antigenicity. Zentralbl. Bakteriol. Parasitenkd. Infektionskr. Hyg. Abt. 1 Orig. 280: Passonet, J., G. D. Freidman, and D. P. Vandersteed Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 325: Powell, K. U., G. D. Bell, A. F. Bowden, J. E. Trowell, and P. H. Jones An effective one-week Helicobacter pylori eradication therapy using omeprazole, clarithromycin and metronidazole. Br. J. Clin. Res. 6: Rautelin, H., W. Tee, K. Seppälä, and T. U. Kosunen Ribotyping patterns and emergence of metronidazole resistance in paired clinical samples of Helicobacter pylori. J. Clin. Microbiol. 32: Rautelin, H., K. Seppälä, O.-V. Renkonen, U. Vainio, and T. U. Kosunen Role of metronidazole resistance in therapy of Helicobacter pylori infection. J. Antimicrob. Chemother. 36: Rauws, E. A., and G. N. Tytgat Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 335:

7 1228 SÖRBERG ET AL. ANTIMICROB. AGENTS CHEMOTHER. 38. Smith, M. R., and D. I. Edwards The influence of microaerophilia and anaerobiosis on metronidazole uptake in Helicobacter pylori. J. Antimicrob. Chemother. 36: Sörberg, M., M. Nilsson, and L. E. Nilsson Morphologic conversion of Helicobacter pylori from bacillary form to coccoid form evaluated by bioluminescence, microscopy and viable count. Eur. J. Microbiol. Infect. Dis. 15: Sörberg, M., M. Nilsson, H. Hanberger, and L. E. Nilsson Pharmacodynamic effects of antibiotics and acid pump inhibitors on Helicobacter pylori. Antimicrob. Agents Chemother. 41: Sören, L., M. Nilsson, and L. E. Nilsson Quantitation of antibiotic effects on bacteria by bioluminescence, viable count and quantal analysis. J. Antimicrob. Chemother. 35: Thore, A., S. Ånsehn, A. Lundin, and S. Berman Detection of bacteriuria by luciferase assay of adenosine triphosphate. J. Clin. Microbiol. 1: Versalovic, J., D. Shortridge, K. Kimbler, M. V. Griffy, J. Beyer, R. K. Flamm, S. K. Tanaka, D. Y. Graham, and M. F. Go Mutations in 23S rrna are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 40: Xia, H., M. Buckley, D. Hyde, C. T. Kaene, and C. A. O Morain Effects of antibiotic-resistance on clarithromycin-combined triple therapy for Helicobacter pylori. Gut 37(Suppl. 1):A55. (Abstract 218.) 45. Xia, H., M. Buckley, C. T. Keane, and C. A. O Morain Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro. J. Antimicrob. Chemother. 37: Xia, H., M. A. Daw, S. Sant, S. Beattie, C. T. Keane, and C. A. O Morain Clinical efficacy of triple therapy in Helicobacter pylori-associated duodenal ulcer. Eur. J. Gastroenterol. Hepatol. 5: Zwet, A. A., J. C. Thijs, W. Schievink-de Vries, J. Schiphuis, and J. A. M. Snijder In vitro studies on stability and development of metronidazole resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 38: Zwet, A. A., J. C. Thijs, and B. de Graaf Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains. Antimicrob. Agents Chemother. 39:

Rapid increase in the prevalence of metronidazole resistant Helicobacter pylori in the Netherlands.

Rapid increase in the prevalence of metronidazole resistant Helicobacter pylori in the Netherlands. Chapter 2 Rapid increase in the prevalence of metronidazole resistant Helicobacter pylori in the Netherlands. E.J.van der Wouden 1, A.A.van Zwet 2, J.C.Thijs 1, G.D.C.Vosmaer 3, J.A.J.Oom 4, A.de Jong

More information

Antibiotic resistance in Helicobacter pylori infection

Antibiotic resistance in Helicobacter pylori infection Antibiotic resistance in Helicobacter pylori infection Francis Megraud haboratoire de Bacteriologie, Hopital Pellegrin, Bordeaux, France Resistance to antibiotics is considered as the primary reason for

More information

Heterogeneity in Susceptibility to Metronidazole among Helicobacter pylori Isolates from Patients with Gastritis or Peptic Ulcer Disease

Heterogeneity in Susceptibility to Metronidazole among Helicobacter pylori Isolates from Patients with Gastritis or Peptic Ulcer Disease JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 1996, p. 2158 2162 Vol. 34, No. 9 0095-1137/96/$04.00 0 Copyright 1996, American Society for Microbiology Heterogeneity in Susceptibility to Metronidazole among

More information

Antibiotic susceptibilities of Helicobacter pylori strains isolated in the Province of Alberta

Antibiotic susceptibilities of Helicobacter pylori strains isolated in the Province of Alberta ORIGINAL ARTICLE Antibiotic susceptibilities of Helicobacter pylori strains isolated in the Province of Alberta Diane E Taylor PhD 1, Qin Jiang MSc 1, Richard N Fedorak MD 2 DE Taylor, Q Jiang, RN Fedorak.

More information

The role of antisecretory drugs in the treatment of Helicobacter pylori infection

The role of antisecretory drugs in the treatment of Helicobacter pylori infection Aliment Pharmacol Ther 1997; 11 (Suppl. 1): 21 25. The role of antisecretory drugs in the treatment of Helicobacter pylori infection W. L. PETERSON Department of Internal Medicine, University of Texas

More information

ORIGINAL ARTICLE /j X x

ORIGINAL ARTICLE /j X x ORIGINAL ARTICLE 10.1111/j.1198-743X.2004.00779.x Laboratory handling of Helicobacter pylori critically influences the results of in-vitro metronidazole resistance determination T. H. Henriksen 1, F. Lerang

More information

Susceptibility of Helicobacter pylori to Bactericidal Properties of Medium-Chain Monoglycerides and Free Fatty Acids

Susceptibility of Helicobacter pylori to Bactericidal Properties of Medium-Chain Monoglycerides and Free Fatty Acids ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1996, p. 302 306 Vol. 40, No. 2 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Susceptibility of Helicobacter pylori to Bactericidal

More information

Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pyloni

Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pyloni Gut 1995; 37: 477-481 Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pyloni 477 Centre for Digestive Diseases, Five Dock, NSW, Australia T J Borody P Andrews G Fracchia S Brandl

More information

High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong

High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong Title High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong Author(s) Wang, WH; Wong, BCY; Mukhopadhyay, AK; Berg, DE; Cho, CH; Lai, KC;

More information

The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori

The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori Aliment Pharmacol Ther 1999; 13: 667±673. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori A. PILOTTO*, G. LEANDRO, M. FRANCESCHI*, M. RASSUà,

More information

Helicobacter pylori Eradication Therapy Success Regarding Different Treatment Period Based on Clarithromycin or Metronidazole Triple-Therapy Regimens

Helicobacter pylori Eradication Therapy Success Regarding Different Treatment Period Based on Clarithromycin or Metronidazole Triple-Therapy Regimens Helicobacter ISSN 1523-5378 Filipec Blackwell Oxford, HEL 1083-4389 1523-5378 Journal XXX Original H. 2008 pylori Kanizaj compilation The UK Eradication Publishing Article Authors et al. Ltd 2008 Therapy

More information

/01/$ DOI: /AAC Copyright 2001, American Society for Microbiology. All Rights Reserved.

/01/$ DOI: /AAC Copyright 2001, American Society for Microbiology. All Rights Reserved. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2001, p. 1500 1504 Vol. 45, No. 5 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.5.1500 1504.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.

More information

Treatment of H. pylori Infection: The Reality

Treatment of H. pylori Infection: The Reality YALE JOURNAL OF BIOLOGY AND MEDICINE 71 (1998), pp. 119-124. Copyright 1999. All rights reserved. Treatment of H. pylori Infection: The Reality Nimish Vakil University of Wisconsin Medical School, Milwaukee

More information

H. pylori Antigen ELISA Kit

H. pylori Antigen ELISA Kit H. pylori Antigen ELISA Kit Catalog Number KA3142 96 assays Version: 04 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle of

More information

One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers

One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers Aliment Pharmacol Ther 1997; 11: 89 93. One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers J. LABENZ*, J.-P. IDSTRO M, B. TILLENBURG*,

More information

What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori?

What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori? What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori? Sequential Therapy Versus Standard Triple- Drug Therapy for Helicobacter pylori

More information

Role of antimicrobial susceptibility testing on ef cacy of triple therapy in Helicobacter pylori eradication

Role of antimicrobial susceptibility testing on ef cacy of triple therapy in Helicobacter pylori eradication Aliment Pharmacol Ther 2000; 14: 1639±1643. Role of antimicrobial susceptibility testing on ef cacy of triple therapy in Helicobacter pylori eradication S. TORACCHIO*, L. CELLINI, E.DICAMPLI, G.CAPPELLO*,M.G.MALATESTA*,A.FERRI*,

More information

Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W.

Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. UvA-DARE (Digital Academic Repository) Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. Link to publication Citation for published

More information

F Mirshahi, G Fowler, A Patel, G Shaw

F Mirshahi, G Fowler, A Patel, G Shaw 22 The School of Health and Sports Science, The University of North London, Holloway Road, London N7 8DB, UK F Mirshahi G Fowler A Patel G Shaw Correspondence to: Dr Shaw. Accepted for publication 11 November

More information

Antimicrobial effectiveness of furazolidone against metronidazoleresistant strains of Helicobacter pylori

Antimicrobial effectiveness of furazolidone against metronidazoleresistant strains of Helicobacter pylori 286 La Revue de Santé de la Méditerranée orientale, Vol. 12, N o 3/4, 2006 Antimicrobial effectiveness of furazolidone against metronidazoleresistant strains of Helicobacter pylori R. Safaralizadeh, 1

More information

ACCEPTED. Comparison of disk diffusion and agar dilution methods for erythromycin and

ACCEPTED. Comparison of disk diffusion and agar dilution methods for erythromycin and AAC Accepts, published online ahead of print on January 00 Antimicrob. Agents Chemother. doi:./aac.000-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

Distribution of Antibiotic MICs for Helicobacter pylori Strains over a 16-Year Period in Patients from Seoul, South Korea

Distribution of Antibiotic MICs for Helicobacter pylori Strains over a 16-Year Period in Patients from Seoul, South Korea ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2004, p. 4843 4847 Vol. 48, No. 12 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.12.4843 4847.2004 Copyright 2004, American Society for Microbiology. All Rights

More information

Antibiotic Susceptibility of Helicobacter pylori Clinical Isolates: Comparative Evaluation of Disk-Diffusion and E-Test Methods

Antibiotic Susceptibility of Helicobacter pylori Clinical Isolates: Comparative Evaluation of Disk-Diffusion and E-Test Methods CURRENT ROBIOLOGY Vol. 53 (2006), pp. 329 334 DOI: 10.1007/s00284-006-0143-1 Current Microbiology An International Journal ª Springer Science+Business Media, Inc. 2006 Antibiotic Susceptibility of Helicobacter

More information

Proton pump inhibitor (proton pump inhibitor)-based triple therapies using clarithromycin in combination SUMMARY INTRODUCTION

Proton pump inhibitor (proton pump inhibitor)-based triple therapies using clarithromycin in combination SUMMARY INTRODUCTION Aliment Pharmacol Ther 2003; 18: 799 804. doi: 10.1046/j.1365-2036.2003.01764.x Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter

More information

The annual incidence of peptic ulcer disease in developed

The annual incidence of peptic ulcer disease in developed CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2003;1:273 278 Pretreatment Antimicrobial Susceptibility Testing Is Cost Saving in the Eradication of Helicobacter pylori MARCO ROMANO,* RICCARDO MARMO, ANTONIO

More information

Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W.

Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. UvA-DARE (Digital Academic Repository) Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. Link to publication Citation for published

More information

Antibiotic Resistance of Helicobacter pylori Strains in Japanese Children

Antibiotic Resistance of Helicobacter pylori Strains in Japanese Children JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2002, p. 649 653 Vol. 40, No. 2 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.2.649 653.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. Antibiotic

More information

Efficacy and Tolerability of a Third-Line, Levofloxacin-Based, 10-Day Sequential Therapy in Curing Resistant Helicobacter Pylori Infection

Efficacy and Tolerability of a Third-Line, Levofloxacin-Based, 10-Day Sequential Therapy in Curing Resistant Helicobacter Pylori Infection ORIGInAL PAPERs Efficacy and Tolerability of a Third-Line, Levofloxacin-Based, 10-Day Sequential Therapy in Curing Resistant Helicobacter Pylori Infection Antonio Tursi 1, Marcello Picchio 2, Walter Elisei

More information

Antibiotic resistance is now often understood at the VIEWPOINTS IN DIGESTIVE DISEASES

Antibiotic resistance is now often understood at the VIEWPOINTS IN DIGESTIVE DISEASES GASTROENTEROLOGY 1998;115:1272 1277 VIEWPOINTS IN DIGESTIVE DISEASES Antibiotic Resistance in Helicobacter pylori: Implications for Therapy DAVID Y. GRAHAM Department of Medicine, Veterans Affairs Medical

More information

Exposure to Metronidazole In Vivo Readily Induces Resistance in Helicobacter pylori and Reduces the Efficacy of Eradication Therapy in Mice

Exposure to Metronidazole In Vivo Readily Induces Resistance in Helicobacter pylori and Reduces the Efficacy of Eradication Therapy in Mice ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1999, p. 777 781 Vol. 43, No. 4 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Exposure to Metronidazole In Vivo

More information

JJBS Jordan Journal of Biological Sciences

JJBS Jordan Journal of Biological Sciences JJBS Jordan Journal of Biological Sciences Volume 4, Number 2, June 2011 ISSN 1995-6673 Pages 71-76 Prevalence of Helicobacter Pylori Gastritis at the North of Jordan N. M. Abu-Ahmad, A. Odeh and A-K.

More information

Prevpac Pylera Omeclamox-Pak

Prevpac Pylera Omeclamox-Pak Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.21 Subject: -Pak Page: 1 of 5 Last Review Date: September 20, 2018 -Pak Description (lansoprazole,

More information

(Index words: Clarithromycin, compliance, efficacy, tinidazole and omeprazole therapy)

(Index words: Clarithromycin, compliance, efficacy, tinidazole and omeprazole therapy) Comparison of one week and two weeks of triple therapy for the eradication of Helicobacter pylori in a Sri Lankan population: a randomised, controlled study HA de Silva 1, J Hewavisenthi 2, A Pathmeswaran

More information

Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates

Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates cp60392 Module 1 Journal of Clinical Pathology 28/8/08 12:38:20 Topics: ; Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical

More information

The discovery of the key role of Helicobacter pylori

The discovery of the key role of Helicobacter pylori GASTROENTEROLOGY 1998;115:1278 1282 Epidemiology and Mechanism of Antibiotic Resistance in Helicobacter pylori FRANCIS MÉGRAUD Laboratoire de Bactériologie, Hôpital Pellegrin, Université Victor Segalen,

More information

COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION

COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,

More information

Helicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.

Helicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35. An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Factors influencing the results of metronidazole resistance testing Elisabeth Nagy Institute of Clinical Microbiology, University of Szeged, National Anaerobe Reference Laboratory, Szeged, Hungary Postgraduate

More information

H elicobacter pylori and aspirin are the two most important

H elicobacter pylori and aspirin are the two most important 490 HELICOBACTER PYLORI Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents W H Wang, W M Wong, D Dailidiene, D E Berg, Q Gu, KCLai,SKLam,BCYWong...

More information

Nicola C. Elviss, 1,2 Robert J. Owen, 1 Aodhan Breathnach, 3 Catherine Palmer 4 and Nandini Shetty 4 INTRODUCTION

Nicola C. Elviss, 1,2 Robert J. Owen, 1 Aodhan Breathnach, 3 Catherine Palmer 4 and Nandini Shetty 4 INTRODUCTION Journal of Medical Microbiology (2005), 54, 567 574 DOI 10.1099/jmm.0.45896-0 Helicobacter pylori antibiotic-resistance patterns and risk factors in adult dyspeptic patients from ethnically diverse populations

More information

JAC Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study

JAC Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study Journal of Antimicrobial Chemotherapy (1998) 41, Suppl. B, 29 35 JAC Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study T. Malizia

More information

Urea Breath Test for Diagnosis of Helicobactor pylori. Original Policy Date 12:2013

Urea Breath Test for Diagnosis of Helicobactor pylori. Original Policy Date 12:2013 MP 2.04.04 Urea Breath Test for Diagnosis of Helicobactor pylori Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date 12:2013 Return to Medical Policy Index

More information

Original article J Bas Res Med Sci 2015; 2(4):45-50.

Original article J Bas Res Med Sci 2015; 2(4):45-50. Comparison between the effectiveness of Furazolidone and Clarithromycin on eradication of helicobacter pylori among patients with peptic ulcer Asghar Rahmani 1, Ali Jafari Haidarloo 2, Hoda Mabrokzadeh

More information

Received 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005

Received 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005 Journal of Antimicrobial Chemotherapy (2005) 56, 1047 1052 doi:10.1093/jac/dki362 Advance Access publication 20 October 2005 Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity,

More information

Determination of MIC & MBC

Determination of MIC & MBC 1 Determination of MIC & MBC Minimum inhibitory concentrations (MICs) are defined as the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight

More information

Comparison of Fluorescent In Situ Hybridization and Conventional Culturing for Detection of Helicobacter pylori in Gastric Biopsy Specimens

Comparison of Fluorescent In Situ Hybridization and Conventional Culturing for Detection of Helicobacter pylori in Gastric Biopsy Specimens JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2001, p. 304 308 Vol. 39, No. 1 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.1.304 308.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Comparison

More information

Helicobacter pylori: Diagnosis, treatment and risks of untreated infection

Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb

More information

Received 17 August 2010/Returned for modification 7 December 2010/Accepted 16 December 2010

Received 17 August 2010/Returned for modification 7 December 2010/Accepted 16 December 2010 ANTIMICROBIAL AGENTS AND CHEMOTHERAY, Mar. 2011, p. 1123 1129 Vol. 55, No. 3 0066-4804/11/$12.00 doi:10.1128/aac.01131-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Genotypic

More information

Treating H. pylori in 2016

Treating H. pylori in 2016 Treating H. pylori in 2016 William D. Chey, MD, FACG Professor of Medicine University of Michigan The Case: A 38 yo Russian man presents with recurrent epigastric pain which occurs after meals and sometimes

More information

Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study

Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study Aliment Pharmacol Ther 2001; 15: 843±849. Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study B. C. Y. WONG*, W. H. WANG*, W.M.WONG*,G.K.K.LAU*,F.M.Y.FUNG*,N.N.S.KUNGà,

More information

Rates of clarithromycin resistance in Helicobacter pylori sampled from healthy subjects in Cheonan, Korea

Rates of clarithromycin resistance in Helicobacter pylori sampled from healthy subjects in Cheonan, Korea Rates of clarithromycin resistance in Helicobacter pylori sampled from healthy subjects in Cheonan, Korea Young Sam Yuk 1, Ga-Yeon Kim 2 1. Department of Biomedical Laboratory Science, Dankook University

More information

H. pylori IgM CLIA kit

H. pylori IgM CLIA kit H. pylori IgM CLIA kit Cat. No.:DEEL0251 Pkg.Size:96 tests Intended use Helicobacter pylori IgM Chemiluminescence ELISA is intended for use in evaluating the serologic status to H. pylori infection in

More information

Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment

Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment Aliment Pharmacol Ther 2003; 18: 93 100. doi: 10.1046/j.0269-2813.2003.01649.x Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily

More information

Perspectives from Viet Nam

Perspectives from Viet Nam International Symposium I (Management of antibiotics-resistant Helicobacter pylori infection) Perspectives from Viet Nam Vu Van Khien 1,HoDangQuyDung 2, Tran Thanh Binh 2 1 Department of GI Endoscopy,

More information

See external label 2 C-8 C Σ=96 tests Cat # 1505Z. MICROWELL ELISA H.Pylori IgA Cat # 1505Z

See external label 2 C-8 C Σ=96 tests Cat # 1505Z. MICROWELL ELISA H.Pylori IgA Cat # 1505Z DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external

More information

Treatment of Helicobacter pylori Infection

Treatment of Helicobacter pylori Infection Treatment of Helicobacter pylori Infection Epidemiology of H. pylori infection (North America) Which are the high risk groups? Epidemiology of H. pylori infection (North America) Which are the high risk

More information

H.pylori IgA Cat #

H.pylori IgA Cat # DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external

More information

S. aureus NCTC 6571, E. coli NCTC (antibiotic

S. aureus NCTC 6571, E. coli NCTC (antibiotic ISO Sensitivity Test Agar Code: KM1204 A semi-defined nutritionally rich sensitivity medium. It is composed of specially selected peptones with a small amount of glucose, solidified with a very pure agar

More information

EFFECT OF SOME CHEMICAL AND PHYSICAL FACTORS ON THE COCCI SHAPE FORMATION OF HELICOBACTER PYLORI ISOLATED FROM PATIENTS WITH DUODENUM ULCER

EFFECT OF SOME CHEMICAL AND PHYSICAL FACTORS ON THE COCCI SHAPE FORMATION OF HELICOBACTER PYLORI ISOLATED FROM PATIENTS WITH DUODENUM ULCER . Helicobacter pylori. Helicobacterpylori (Duodenal ulcer) (Ski row medium) H. pylori (Nalidixic Acid).(Cephalothin) H. pylori (%). ( ) ().(86.9) (PH) (%) EFFECT OF SOME CHEMICAL AND PHYSICAL FACTORS ON

More information

H.Pylori IgG

H.Pylori IgG DIAGNOSTIC AUTOMATION, INC. 21250 Califa Street, Suite 102 and116, Woodland Hills, CA 91367 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com

More information

H.Pylori IgG Cat # 1503Z

H.Pylori IgG Cat # 1503Z DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external

More information

RESEARCH ARTICLE. Abstract. Introduction

RESEARCH ARTICLE. Abstract. Introduction DOI:10.22034/APJCP.2017.18.4.927 Outcomes of a Randomized Controlled Trial Comparing Modified High Dose Omeprazole RESEARCH ARTICLE Outcomes of a Randomized Controlled Trial Comparing Modified High Dose

More information

Multicenter Survey of Routine Determinations of Resistance of Helicobacter pylori to Antimicrobials over the Last 20 Years (1990 to 2009) in Belgium

Multicenter Survey of Routine Determinations of Resistance of Helicobacter pylori to Antimicrobials over the Last 20 Years (1990 to 2009) in Belgium JOURNAL OF CLINICAL MICROBIOLOGY, June 2011, p. 2200 2209 Vol. 49, No. 6 0095-1137/11/$12.00 doi:10.1128/jcm.02642-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multicenter

More information

H. pylori IgM. Cat # H. pylori IgM ELISA. ELISA: Enzyme Linked Immunosorbent Assay. ELISA - Indirect; Antigen Coated Plate

H. pylori IgM. Cat # H. pylori IgM ELISA. ELISA: Enzyme Linked Immunosorbent Assay. ELISA - Indirect; Antigen Coated Plate DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com H. pylori

More information

ORIGINAL INVESTIGATION. Effectiveness of Helicobacter pylori Therapies in a Clinical Practice Setting

ORIGINAL INVESTIGATION. Effectiveness of Helicobacter pylori Therapies in a Clinical Practice Setting ORIGINAL INVESTIGATION Effectiveness of Helicobacter pylori Therapies in a Clinical Practice Setting M. Brian Fennerty, MD; David A. Lieberman, MD; Nimish Vakil, MD; Nathan Magaret; Douglas O. Faigel,

More information

Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED

Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients

Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients Blackwell Science, LtdOxford, UKJGHJournal of Gastroenterology and Hepatology0815-93192005 Blackwell Publishing Asia Pty Ltd206935940Original ArticleLow-dose rabeprazole-based triple therapywm Wong et

More information

[PHAR06] Anti Helicobacter pylori from extracts of ten species of Phyllanthus sp. with special emphasis on chloroform extracts of Phyllanthus pulcher

[PHAR06] Anti Helicobacter pylori from extracts of ten species of Phyllanthus sp. with special emphasis on chloroform extracts of Phyllanthus pulcher The th Annual Seminar of National Science Fellowship [PHAR] Anti Helicobacter pylori from extracts of ten species of Phyllanthus sp. with special emphasis on chloroform extracts of Phyllanthus pulcher

More information

Basis for the Selective Antibacterial Activity In Vitro of Proton Pump Inhibitors against Helicobacter spp.

Basis for the Selective Antibacterial Activity In Vitro of Proton Pump Inhibitors against Helicobacter spp. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1997, p. 1797 1801 Vol. 41, No. 8 0066-4804/97/$04.00 0 Copyright 1997, American Society for Microbiology Basis for the Selective Antibacterial Activity In Vitro

More information

Biological Consulting Services

Biological Consulting Services Biological Consulting Services of North Florida/ Inc. May 13, 2009 Aphex BioCleanse Systems, Inc. Dear Sirs, We have completed antimicrobial efficacy study on the supplied Multi-Purpose Solution. The testing

More information

Clinical practice - breath tests

Clinical practice - breath tests Clinical practice - breath tests G D Bell Gastroenterology Department, Sunderland District General Hospital, Sunderland, UK The underlying principle of the two non-invasive radio-labelled urea breath tests

More information

Metronidazole resistance and virulence factors in Helicobacter pylori as markers for treatment failure in a paediatric population

Metronidazole resistance and virulence factors in Helicobacter pylori as markers for treatment failure in a paediatric population FEMS Immunology and Medical Microbiology 24 (1999) 183^188 Metronidazole resistance and virulence factors in Helicobacter pylori as markers for treatment failure in a paediatric population Abstract Manuel

More information

H.Pylori IgM Cat # 1504Z

H.Pylori IgM Cat # 1504Z DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external

More information

Disclosures. Co-founder and Chief Science Officer, TechLab

Disclosures. Co-founder and Chief Science Officer, TechLab H. pylori testing Disclosures Co-founder and Chief Science Officer, TechLab Learning Objectives Evaluate the appropriate testing methodology by balancing performance, economics, and workflow. Discuss the

More information

I. Kalfus MD, D. Riff MD, R. Fathi PhD, D. Graham MD

I. Kalfus MD, D. Riff MD, R. Fathi PhD, D. Graham MD A Randomized Double Blind Placebo Controlled Phase III Study to Assess the Safety and Efficacy of Rifabutin Triple Therapy (RHB-105) for Helicobacter pylori (H. pylori) Infection in Dyspepsia Patients

More information

Rifampin Resistance. Charlottesville, Virginia i0w organisms in Trypticase soy broth (BBL Microbiology

Rifampin Resistance. Charlottesville, Virginia i0w organisms in Trypticase soy broth (BBL Microbiology ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1980, p. 658-662 0066-4804/80/04-0658/05$02.00/0 Vol. 17, No. 14 Treatment of Experimental Staphylococcal Infections: Effect of Rifampin Alone and in Combination

More information

High use of maintenance therapy after triple therapy regimes in Ireland

High use of maintenance therapy after triple therapy regimes in Ireland High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity

More information

Title. Author(s)Kato, Mototsugu. Issue Date Doc URL. Type. Note. File Information.

Title. Author(s)Kato, Mototsugu. Issue Date Doc URL. Type. Note. File Information. Title Effects of lansoprazole plus amoxycillin on the cure Author(s)Kato, Mototsugu Issue Date 1996-12-25 Doc URL http://hdl.handle.net/2115/32629 Type theses (doctoral) Note 共著者あり 共著者名 :Asaka Masahiro,

More information

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection ACG Clinical Guideline: Treatment of Helicobacter pylori Infection William D. Chey, MD, FACG 1, Grigorios I. Leontiadis, MD, PhD 2, Colin W. Howden, MD, FACG 3 and Steven F. Moss, MD, FACG 4 1 Division

More information

Helicobacter pyloni and upper gastrointestinal

Helicobacter pyloni and upper gastrointestinal 314 Helicobacter pyloni and upper gastrointestinal disease: a survey of gastroenterologists in the United Kingdom Gut 1995; 37: 314-318 R Milne, R P H Logan, D Harwood, J J Misiewicz, D Forman Health Services

More information

One week triple therapy for Helicobacter pylori:a multicentre comparative study

One week triple therapy for Helicobacter pylori:a multicentre comparative study Gut 1997; 41: 735 739 735 PAPERS Central Middlesex Hospital, London J J Misiewicz A W Harris Rotherham District Hospital K D Bardhan Northwick Park Hospital, Slough S Levi The Meath Hospital, Dublin C

More information

SURVEY IN IRAN OF CLARITHROMYCIN RESISTANCE IN HELICOBACTER PYLORI ISOLATES BY PCR-RFLP

SURVEY IN IRAN OF CLARITHROMYCIN RESISTANCE IN HELICOBACTER PYLORI ISOLATES BY PCR-RFLP SURVEY IN IRAN OF CLARITHROMYCIN RESISTANCE IN HELICOBACTER PYLORI ISOLATES BY PCR-RFLP Nourkhoda Sadeghifard 1, Teimour Seidnazari 1, Sobhan Ghafourian 1,3, Mohammad Soleimani 2, Abbas Maleki 1, Mostafa

More information

SMT19969: A Selective Therapy for C. difficile Infection

SMT19969: A Selective Therapy for C. difficile Infection SMT19969: A Selective Therapy for C. difficile Infection One Bug, One Drug 25 th September 2012 SMT19969: A Selective Therapy for CDI SMT19969 is a novel antibiotic for the specific treatment of Clostridium

More information

Treatment of Helicobacter pylori in Patients With Duodenal Ulcer Hemorrhage A Long-Term Randomized, Controlled Study

Treatment of Helicobacter pylori in Patients With Duodenal Ulcer Hemorrhage A Long-Term Randomized, Controlled Study THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 95, No. 9, 2000 2000 by Am. Coll. of Gastroenterology ISSN 0002-9270/00/$20.00 Published by Elsevier Science Inc. PII S0002-9270(00)01041-8 Treatment of Helicobacter

More information

Specific therapeutic schemes of omeprazole

Specific therapeutic schemes of omeprazole AAC Accepts, published online ahead of print on 1 June 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.00158-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.

More information

Susceptibility of Helicobacter Pylori to Antibiotics: a Study of Prevalence in Patients with Dyspepsia in Quito, Ecuador

Susceptibility of Helicobacter Pylori to Antibiotics: a Study of Prevalence in Patients with Dyspepsia in Quito, Ecuador DOI: https://doi.org/.5/57.7 Susceptibility of Helicobacter Pylori to Antibiotics: a Study of Prevalence in Patients with Dyspepsia in Quito, Ecuador Jorge Reyes Ch., Katherine Guzmán, Eduardo Morales,

More information

Helicobacter Pylori: Treatment Rates and Strategies for Improvement in a Community Health Center Population

Helicobacter Pylori: Treatment Rates and Strategies for Improvement in a Community Health Center Population Eileen Condon October 28, 2011 SEARCH Program Abstract Background Helicobacter Pylori: Treatment Rates and Strategies for Improvement in a Community Health Center Population Gastric cancer is a major global

More information

Sensitivity to nitazoxanide among metronidazole resistant Helicobacter pylori strains in patients with gastritis

Sensitivity to nitazoxanide among metronidazole resistant Helicobacter pylori strains in patients with gastritis Original Article Medical Journal of the Islamic Republic of Iran (MJIRI) Iran University of Medical Sciences Sensitivity to nitazoxanide among metronidazole resistant Helicobacter pylori strains in patients

More information

In vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae

In vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae AAC Accepted Manuscript Posted Online 26 January 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.04127-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 In vitro assessment

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Adherence, to bismuth quadruple therapy, 543 546 Adjuvant therapy, probiotics as, 567 569 Age factors, in gastric cancer, 611 612, 616 AID protein,

More information

Gilles Jequier. Commercial Director Organobalance, a Novozymes Company

Gilles Jequier. Commercial Director Organobalance, a Novozymes Company "Latest clinical Evidences showing that a proprietary Lactobacillus reuteri Strain can reduce the Symptoms associated with a Helicobacter pylori Infection" Gilles Jequier Commercial Director Organobalance,

More information

Comparison of the Accuracy of Two Commercial Rapid Urase Tests, CLOtest and Pronto Dry, in Detecting Helicobacter pylori Infection ABSTRACT

Comparison of the Accuracy of Two Commercial Rapid Urase Tests, CLOtest and Pronto Dry, in Detecting Helicobacter pylori Infection ABSTRACT Original Article Rojborwonwitaya J, Vijitjunyakul N THAI J GASTROENTEROL 2005 Vol. 6 No. 2 May - Aug. 2005 55 Comparison of the Accuracy of Two Commercial Rapid Urase Tests, CLOtest and Pronto Dry, in

More information

Original Policy Date

Original Policy Date MP 2.04.38 Genetic Testing for Helicobacter pylori Treatment Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return

More information

The term biofilm describes the structurally complex bacterial BRIEF COMMUNICATION

The term biofilm describes the structurally complex bacterial BRIEF COMMUNICATION CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:817 820 BRIEF COMMUNICATION Biofilm Demolition and Antibiotic Treatment to Eradicate Resistant Helicobacter pylori: A Clinical Trial GIOVANNI CAMMAROTA,*

More information

Management of dyspepsia and of Helicobacter pylori infection

Management of dyspepsia and of Helicobacter pylori infection Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia

More information

Analysis of Gene Mutations Associated with Antibiotic Resistance in Helicobacter pylori Strains Isolated from Korean Patients

Analysis of Gene Mutations Associated with Antibiotic Resistance in Helicobacter pylori Strains Isolated from Korean Patients ORIGINAL ARTICLE ISSN 1738-3331, http://dx.doi.org/10.7704/kjhugr.2014.14.2.95 The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2014;14(2):95-102 Analysis of Gene Mutations Associated

More information

ORIGINAL ARTICLE /j x

ORIGINAL ARTICLE /j x ORIGINAL ARTICLE.1111/j.1469-691.6.1514.x Comparison of the performance of serological kits for Helicobacter pylori infection with European and Asian study populations T. T. H. Hoang 1,4, A.-S. Rehnberg

More information

Eradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin

Eradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin CASE REPORT Eradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin Takahisa Furuta 1, Mitsushige Sugimoto 2, Mihoko Yamade

More information